system: You are a contract-analysis assistant performing a span-extraction task. You are given an excerpt from a commercial contract and the name of a clause type to locate within it.

Return the exact text of the requested clause, copied verbatim from the excerpt — identical wording and punctuation, with no paraphrasing, summarising, explanation, or added commentary.

The excerpt is one window of a much longer contract and often will not contain the requested clause. If the requested clause does not appear in this excerpt, respond with exactly: Not found.

Output only the extracted clause text, or the exact string `Not found.` — nothing else.

user: Contract excerpt:
"""
information disclosed by the Parties under this Agreement. Either Party may disclose the terms of this Agreement to the extent required, in the reasonable opinion of such Party's legal counsel, to comply with applicable Law, including the rules and regulations promulgated by the United States Securities and Exchange Commission or any equivalent governmental agency in any country in the Territory. Before disclosing this Agreement or any of the terms hereof pursuant to this Section 11.15(a), the Parties will consult with one another on the terms of this Agreement to be redacted in making any such disclosure (which, at a minimum, shall include redaction of certain financial terms), with the disclosing Party providing as much advance notice as is feasible under the circumstances, and giving consideration to the comments of the other Party. Further, if a Party discloses this Agreement or any of the terms hereof in accordance with this Section 11.15(a), such Party shall, at its own expense, seek such confidential treatment of confidential portions of this Agreement, as may be reasonably requested by the other Party. (b) No Party to this Agreement shall originate any publicity, news release or other similar public announcement, written or oral, whether relating to this Agreement or any documents or transactions contemplated hereby or the existence of any arrangement between the Parties, without the prior written consent of the other Party whether or not named in such publicity, news release or other similar public announcement, except to the extent permitted under the License Agreement. 11.16 Bankruptcy. All rights and licenses granted under or pursuant to this Agreement by a Party to the other are and will otherwise be deemed to be, for purposes of Section 365(n) of the Bankruptcy Code, licenses of right to "intellectual property" as defined under Section 101 of the Bankruptcy Code. The Parties agree that Vericel and its Sublicensees, 30 9012190/26 as Sublicensees of such rights under this Agreement, will retain and may fully exercise all of their rights and elections under the Bankruptcy Code and any foreign counterpart thereto. [SIGNATURE PAGE FOLLOWS] 31 9012190/26 IN WITNESS WHEREOF, the Parties hereto have each caused this Agreement to be duly executed as of the Effective Date. MEDIWOUND LTD. By: /s/ Stephen T. Wills Name: Stephen T. Wills Title: Chairman VERICEL CORPORATION By: /s/ Dominick Colangelo Name: Dominick Colangelo Title: President & CEO 32 9012190/26 SCHEDULE 1.26 KEY MATERIALS & KEY MATERIALS SUPPLIERS Bromelain special Production - CBC Taiwan [***] [***] 33 9012190/26 SCHEDULE 2.7 TECHNOLOGY TRANSFER DOCUMENTATION Technology Transfer documents include but are not limited to [***] 34 9012190/26 SCHEDULE 4.1 CHANGE NOTIFICATION Category of Change Minimum Notification prior to effectiveness of implementation of the change Section 4.2 : Changes in Facility Major - Changes to facility have the potential to have an adverse effect on product quality that requires BLA Prior Approval Supplement. [***] • Moderate - Changes to facility have a moderate potential to have an adverse effect on product quality that requires Notification to the Regulatory Authority (e.g., CBE, CBE-30) [***] • Minor - Changes to facility have minimal potential to have an adverse effect on product quality that requires annual or periodic reporting to the FDA. [***] Section 4.3: Discretionary Manufacturing changes • Major - Changes have the potential to have an adverse effect on product quality that requires BLA Prior Approval Supplement. [***] • Moderate - Changes have a moderate potential to have an adverse effect on product quality that requires Notification to the Regulatory Authority (e.g., CBE, CBE-30). [***] 35 9012190/26 Category of Change Minimum Notification prior to effectiveness of implementation of the change • Minor - Changes have minimal potential to have an adverse effect on product quality that requires annual or periodic reporting to the FDA. [***] • None - Changes have no potential to have an adverse effect on product quality and has no regulatory impact. • Example o Clarification of internal SOPs [***] Section 4.4 Changes required by a Regulatory Authority [***] Example Timeline for Major Change (BLA Prior Approval Supplement Required) Vericel Evaluation: [***] Pre-Submission discussions with FDA and/or BARDA: [***] Testing (presumes rate limitation is stability testing of > 6 months): [***] Submission drafting: [***] FDA Review: [***] Implementation: [***] Example Timeline for Moderate Change (BLA CBE-30 Required) Vericel Evaluation: [***] Testing: [***] Submission drafting: [***] FDA Review: [***] Implementation: [***] 36 9012190/26 SCHEDULE 4.5 FULL-TIME EQUIVALENT FTE Rates for Reimbursement of Preapproved Activities Completed by MediWound per Section 4.5: The FTE rate will be capped per [***]. MediWound
"""

Extract the exact clause related to "Unlimited/All-You-Can-Eat-License" from the excerpt above.

assistant: Not found.